Answers are grounded in this paper and cite their sources.
Mesenchymal stromal cells (MSCs) have been extensively studied as a potential treatment for steroid refractory acute graft-versus-host disease (aGVHD). However, the majority of clinical trials have focused on bone marrow-derived MSCs.
No takes yet. Share an insight, caveat, or question.
Niu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: